Table 4.
Univariable and Multivariable Cox Regression Analyses of Progression-Free Survival
| Variable | Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age, yr | 0.97 (0.95–0.99) | 0.004 | 0.97 (0.94–1.00) | 0.024 | |
| Male sex | 0.77 (0.43–1.35) | 0.357 | |||
| ALBI grade | 0.047 | 0.020 | |||
| 1 | Reference | Reference | |||
| 2 | 1.66 (1.01–2.73) | 2.22 (1.13–4.34) | |||
| CRAFITY score | |||||
| 0 | Reference | Reference | |||
| 1 | 2.07 (0.96–4.48) | 0.064 | 1.49 (0.64–3.49) | 0.353 | |
| 2 | 3.66 (1.47–9.12) | 0.005 | 3.74 (1.34–10.40) | 0.012 | |
| Etiology | |||||
| Non-viral | Reference | ||||
| Viral | 1.34 (0.71–2.52) | 0.364 | |||
| Macrovascular invasion | 1.42 (0.93–2.53) | 0.093 | 2.27 (1.06–4.87) | 0.035 | |
| Bile duct invasion | 0.77 (0.24–2.45) | 0.652 | |||
| Liver infiltration >50% | 1.61 (0.85–3.04) | 0.141 | |||
| Lung metastasis | 2.44 (1.44–4.15) | <0.001 | 3.94 (1.96–7.91) | <0.001 | |
| LN metastasis | 0.92 (0.52–1.62) | 0.768 | |||
| Bone metastasis | 0.74 (0.37–1.46) | 0.387 | |||
| Combined RT | 0.40 (0.20–0.81) | 0.011 | 0.15 (0.04–0.55) | 0.004 | |
HR, hazard ratio; CI, confidence interval; ALBI, albumin-bilirubin; CRAFITY, C-reactive protein and α-fetoprotein in immunotherapy; LN, lymph node; RT, radiotherapy.